We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+11.87%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.83%
AUM
$1.14B
AUM Growth
+$62.6M
Cap. Flow
-$68.5M
Cap. Flow %
-6%
Top 10 Hldgs %
20.56%
Holding
206
New
27
Increased
44
Reduced
47
Closed
29

Top Buys

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$19M
2
AXSM icon
Axsome Therapeutics
AXSM
+$12M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11.2M
4
CHX
ChampionX
CHX
+$11M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.5M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$15.9M
2
UTHR icon
United Therapeutics
UTHR
+$14.3M
3
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$13.4M
4
STAA icon
STAAR Surgical
STAA
+$11.7M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 44.14%
2 Technology 14.06%
3 Industrials 9.62%
4 Energy 8.22%
5 Financials 5.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVX icon
26
Chevron
CVX
$366B
$14.6M 1.28%
81,350
– –
PODD icon
27
Insulet
PODD
$9.79B
$14.4M 1.26%
49,025
+2,207
+5% +$609K
LSCC icon
28
Lattice Semiconductor
LSCC
$18.5B
$14M 1.23%
216,351
-659
-0.3% -$39.8K
VRTX icon
29
Vertex Pharmaceuticals
VRTX
$126B
$13.9M 1.22%
48,241
-14,538
-23% -$4.43M
BILL icon
30
BILL Holdings
BILL
$4.78B
$13.8M 1.21%
126,921
-1,315
-1% -$158K
CUTR
31
DELISTED
Cutera, Inc.
CUTR
$13.6M 1.19%
307,142
+12,540
+4% +$572K
WTFC icon
32
Wintrust Financial
WTFC
$10.7B
$13.3M 1.17%
157,336
+66,017
+72% +$5.83M
VEEV icon
33
Veeva Systems
VEEV
$37.4B
$13.1M 1.14%
80,891
+8,077
+11% +$1.38M
CELH icon
34
Celsius Holdings
CELH
$7.03B
$12.9M 1.13%
372,636
-54,267
-13% -$1.77M
APLS
35
DELISTED
Apellis Pharmaceuticals
APLS
$12.8M 1.12%
248,283
+53,770
+28% +$2.85M
ALNY icon
36
Alnylam Pharmaceuticals
ALNY
$29.3B
$12.6M 1.1%
52,884
+4,582
+9% +$977K
BMRN icon
37
BioMarin Pharmaceuticals
BMRN
$12.4B
$12.4M 1.08%
+119,372
New +$11.2M
CALY
38
Callaway Golf Company
CALY
$3.14B
$12.3M 1.08%
623,888
-2,145
-0.3% -$42.3K
HZNP
39
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$11.8M 1.03%
103,724
-139,397
-57% -$11.6M
SRPT icon
40
Sarepta Therapeutics
SRPT
$1.77B
$11.7M 1.03%
+90,390
New +$10.5M
CHX
41
DELISTED
ChampionX
CHX
$11.6M 1.01%
+398,649
New +$11M
IRDM icon
42
Iridium Communications
IRDM
$5.29B
$10.6M 0.93%
206,048
+24,901
+14% +$1.25M
BAC icon
43
Bank of America
BAC
$442B
$10.5M 0.92%
316,118
+96,118
+44% +$3.31M
MSFT icon
44
Microsoft
MSFT
$3.71T
$10M 0.88%
41,796
-1,771
-4% -$425K
XENE icon
45
Xenon Pharmaceuticals
XENE
$6.12B
$9.95M 0.87%
+252,302
New +$9.19M
GS icon
46
Goldman Sachs
GS
$303B
$9.92M 0.87%
28,894
+5,737
+25% +$2M
WING icon
47
Wingstop
WING
$3.18B
$8.71M 0.76%
63,310
+1,852
+3% +$273K
RRX icon
48
Regal Rexnord
RRX
$11.9B
$8.23M 0.72%
68,615
-377
-0.5% -$49.4K
AAPL icon
49
Apple
AAPL
$4.57T
$8.21M 0.72%
63,189
-15,017
-19% -$2.15M
AVGO icon
50
Broadcom
AVGO
$2.04T
$8.09M 0.71%
144,620
+14,200
+11% +$712K
1
2
3 4 5

Similar funds

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return

Nicholas Investment Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Nicholas Investment Partners held 206 positions worth $1.14B, up 5.8% from $1.08B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Nicholas Investment Partners withdrew a net $68.5M in Q4 2022, closing 29 positions and reducing 47 holdings. Its most notable exit was SpringWorks Therapeutics, an estimated $15.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 44% a quarter earlier, followed by Technology and Industrials.

Against the trend, Nicholas Investment Partners opened a new position in Lantheus worth $15.7M.

  • Nicholas Investment Partners's largest Q4 2022 buy was Lantheus: 308,295 shares worth $15.7M.
  • Nicholas Investment Partners added most to Wintrust Financial in Q4 2022, an estimated $5.83M increase.
  • Nicholas Investment Partners's biggest Q4 2022 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $13.4M.
  • Nicholas Investment Partners fully exited SpringWorks Therapeutics in Q4 2022, selling an estimated $15.9M.
  • Nicholas Investment Partners's ten largest holdings make up 21% of its $1.14B portfolio in Q4 2022.
  • Nicholas Investment Partners opened 27 new positions and closed 29 in Q4 2022.
  • Nicholas Investment Partners's portfolio value rose 5.8% quarter-over-quarter to $1.14B.

Based on Nicholas Investment Partners's 13F filing for Q4 2022, filed 10 Feb 2023.